Introduction {#s1}
============

Methylmercury (MeHg) is a global environmental contaminant targeting the central nervous system (CNS) ([@c38]; [@c80]). Consumption of MeHg-containing fish products ([@c20]; [@c23]; [@c91]; [@c92]) and rice ([@c78]; [@c100]) has been shown to induce neurodegeneration as well as be associated with neurodevelopmental disorders ([@c14]; [@c22]; [@c24]). However, the underlying cellular and molecular mechanisms of MeHg-induced neurotoxicity have yet to be fully elucidated. Meanwhile, there is still a lack of treatment to effectively protect against MeHg-induced brain damage.

Hypoxia-inducible factor-1 (HIF-1), a DNA-binding transcription factor, plays a crucial role in a diverse range of adaptive responses to oxygen tension. HIF-1 is a heterodimer comprising an oxygen-labile $\alpha\text{-submit}$ ($\text{HIF-}1\alpha$) and a constitutively expressed $\beta\text{-submit}$ ($\text{HIF-}1\beta$). Under normal oxygen conditions ($> 5\%$ $O_{2}$), prolyl hydroxylase (PHD) has been shown to mediate hydroxylation of $\text{HIF-}1\alpha$ ([@c15]; [@c50]). Hydroxylated $\text{HIF-}1\alpha$ is rapidly degraded by the ubiquitin proteasome system (UPS), mediated by interaction with the von-Hippel Lindau tumor suppressor gene product (pVHL) ([@c18]; [@c60]). Under hypoxic conditions ($< 5\%$ $O_{2}$) or stimulation by other environmental factors, stabilized $\text{HIF-}1\alpha$ dimerizes with $\text{HIF-}1\beta$ to transactivate a series of adaptive genes, including vascular endothelial growth factor A (VEGF-A), glucose transporter 1 (GLUT-1), and erythropoietin (EPO) ([@c84]). Several metals and organic chemicals have been shown to affect $\text{HIF-}1\alpha$ expression and activity ([@c36]; [@c59]; [@c63]; [@c95]; [@c96]), whereas increased expression of $\text{HIF-}1\alpha$ has been shown to be protective against neurotoxicants ([@c41]; [@c59]; [@c96]). Manganese has also been shown to increase $\text{HIF-}1\alpha$ protein levels in Hep2 cells by regulating mitogen-activated protein kinases (MAPKs) ([@c88]). Clioquinol (a copper and zinc chelator) decreased $\text{HIF-}1\alpha$ degradation by inhibiting $\text{HIF-}1\alpha$ ubiquitination and hydroxylation in SH-SY5Y cells and HepG2 cells, whereas addition of copper and zinc reversed these effects ([@c28]). Cadmium was shown to up-regulate $\text{HIF-}1\alpha$ expression in human lung epithelial cells via the production of reactive oxygen species (ROS) through the activation of the protein kinase B (Akt), and extracellular signal-regulated protein kinase (ERK) signaling pathways ([@c55]). Notably, deferoxamine (DFO), an iron chelator, was shown to attenuate neuronal cell death and the generation of ROS caused by MeHg and methylphenyl tetrahydropyridine (MPTP) in *in vivo* rodent models ([@c42]; [@c58]). Furthermore, it was shown that by inhibiting the activity of proline hydroxylase (PHD) in mouse hippocampal neurons, DFO decreased degradation of $\text{HIF-}1\alpha$ and increased intracellular levels of $\text{HIF-}1\alpha$ protein ([@c44]). Recently, several studies have further documented that $\text{HIF-}1\alpha$ is neuroprotective because it drives the expression of critical genes that diminish neuronal cell death ([@c26]; [@c85]). Increased $\text{HIF-}1\alpha$ expression and activity have been shown to promote glycolysis and glucose metabolism, thus countering oxidative stress by producing NADH and NADPH to propagate neuroprotective responses ([@c90]). $\text{HIF-}1\alpha$ has also been shown to improve cerebral blood flow, which could oppose the toxicity of hypoxia ([@c51]). Overexpression of $\text{HIF-}1\alpha$ and/or $\text{HIF-}1\alpha$ target genes, such as VEGF-A and EPO, may be an early adaptation to the oxidative stressors that characterize MeHg-induced neuropathology. Thus, we speculate that the molecular events that constitute this early adaptation are likely neuroprotective and might mitigate neuronal injury caused by MeHg.

Previous studies have indicated an association between $\text{HIF-}1\alpha$ activity and intracellular ROS production. ROS was reported to promote $\text{HIF-}1\alpha$ accumulation by the inhibition of PHD catalytic activity via the oxidization of PHD-bound $Fe^{2 +}$ ([@c57]; [@c73]). However, it has been noted that a paradox exists between them, because the $\text{HIF-}1\alpha\text{-dependent}$ transcriptional program can prevent mitochondrial ROS generation ([@c53]). It is unclear whether MeHg-induced toxicity is associated with the expression of $\text{HIF-}1\alpha$, whereas the specific relationship between ROS production and $\text{HIF-}1\alpha$ also remains unclear. MeHg predominantly accumulates in the CNS, particularly in astrocytes; the latter have been shown to play an important role in mediating MeHg-induced neurotoxicity ([@c24]; [@c86]), inhibit glutamate uptake, and contribute to secondary excitotoxicity ([@c8]; [@c35]; [@c65], [@c66]). Astrocytes perform diverse important functions in providing support and nutrition ([@c1]; [@c79]), inducing neuronal differentiation ([@c12]) and mediating immune responses ([@c4], [@c5]; [@c54]). Therefore, we aimed to investigate the role of $\text{HIF-}1\alpha$ in MeHg-induced acute neurotoxicity by using primary rat astrocytes and adult rats, with special emphasis on an ROS mode of toxicity, so as to further identify novel therapeutic targets against MeHg-induced neuronal injury.

Materials and Methods {#s2}
=====================

Primary Rat Astrocyte Isolation and Culture {#s2.1}
-------------------------------------------

Sprague-Dawley (SD) rats at the 1--2-d postnatal stage were purchased from the Laboratory Animal Center of Jiangsu University. Primary neonatal rat astrocytes were prepared as previously described ([@c10], [@c11]; [@c37]; [@c97]; [@c99]). The procedures were as follows: Rats were rapidly decapitated, and the cerebral hemispheres were quickly obtained and rinsed with 4°C phosphate buffered solution (PBS). After dissecting away part of the meninges, basal ganglia, midbrain, and blood vessels, the remaining cortical tissues were cut into $1{\,{mm}}^{3}$ pieces and dissociated with 0.25% trypsin (Gibco) for 15 min at room temperature in the absence of stirring. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM; Hyclone) containing 10% fetal bovine serum (Gibco), and 1% penicillin/streptomycin (Gibco). Culture medium was replaced with fresh medium twice a week, and cultures were maintained in a 5% ${CO}_{2}$ environment at 37°C. Cultured cells were used for experiments when astrocytes reached $75\% –85\%$ confluency. Protocols were approved by the Animal Ethics Committee of Jiangsu University of China and were carried out in accordance with the established Guiding Principles for Animal Research.

Reagents and Antibodies {#s2.2}
-----------------------

Methylmercuric chloride (MeHgCl; Sigma-Aldrich) was dissolved in PBS to form a stock concentration of $10\text{ \ mM}$; MG132; 3,4-Dihydroxybenzoic acid (DHB); cobalt chloride ($\text{CoCl}_{2}$); *N*-acetyl-cysteine (NAC) and Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid); and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl diphenyltetrazolium bromide (MTT)\] were obtained from Sigma-Aldrich. Cycloheximide (CHX) was purchased from MedChemExpress; 2-methoxyestradiol (2-MeOE2) was purchased from Selleck Chemicals. For Western blotting analysis, the primary polyclonal antibodies to $\text{HIF-}1\alpha$, VEGF-A, GLUT-1, and EPO were obtained from ImmunoWay, and antibodies to $\text{HIF-}1\beta$ and $\beta\text{-actin}$ were obtained from Cell Signaling Technology and CMATAG, respectively. Secondary antibodies used for immunoblotting included horseradish peroxidase (HRP)-conjugated antimouse (Santa Cruz Biotechnology) or anti-rabbit antibodies (Santa Cruz Biotechnology).

Cell Treatment {#s2.3}
--------------

Astrocytes were treated for $0.5\; h$ with MeHg at concentrations of 1.0, 2.5, 5.0, or $10\;\mu M$ in the medium, and the cells treated by culture medium without MeHg were used as the control group. These concentrations were used in previous studies ([@c2]; [@c87]). $H_{2}O_{2}$ ($6\;\mu M$, $0.5\; h$), CHX ($400\;\mu M$, 0.5, 1, or $2\; h$), MG132 ($1\;\mu M$, $24\; h$), DHB ($1\text{ \ mM}$, $6\; h$), $\text{CoCl}_{2}$ ($200\;\mu M$, $0.5\; h$), 2-MeOE2 ($10\;\mu M$, $0.5\; h$), and NAC ($2.5\text{ \ mM}$, $4\; h$) or Trolox ($2.5\text{ \ mM}$, $4\; h$) were administered prior to MeHg treatment.

Cell Proliferation Assay {#s2.4}
------------------------

Cell proliferation was measured in astrocytes cultured in 96-well plates (${1 \times 10}^{4}/\text{well}$) using the MTT assay. At the end of treatment, MTT was added to each well at a final concentration of $0.5\;{mg}/{mL}$ and incubated at 37°C for $4\; h$. Next, the MTT solution was replaced with dimethyl sulfoxide ($150\;\mu L/\text{well}$) for 10 min to dissolve the dark-blue formazan crystals in intact cells, and the absorbance was measured at $490\text{ \ nm}$ with a Bio-Rad 680 Microplate Reader (Bio-Rad Laboratories).

Lactate Dehydrogenase (LDH) Release Assay {#s2.5}
-----------------------------------------

Cytotoxicity was detected using an LDH release assay kit (Jiancheng Bioengineering Institute of Nanjing) according to the manufacturer's protocol. Cells were cultured in 96-well plates ($1 \times 10^{4}/\text{well}$), and after treatment supernatants were transferred to clean 96-well plates. Absorbance was analyzed at $450\text{ \ nm}$ using a Bio-Rad 680 Microplate Reader.

Measurement of Intracellular ROS Generation {#s2.6}
-------------------------------------------

To measure ROS generation, a fluorometric assay was carried out using the cell membrane permeable dye 2′,7′-dichlorofluorescin diacetate (DCFH-DA). In the quantitative experiment of fluorescence intensity, cells cultured in 96-well plate ($1 \times 10^{4}/\text{well}$) were treated with different concentrations of MeHg (1, 2.5, 5, and $10\;\mu M$) for $0.5\; h$ and were then incubated with $10\;\mu\text{mol}/L$ DCFH-DA in serum-free medium for $0.5\; h$ at 37°C. After washing with PBS, the fluorescence intensity was measured with Cytation™ 5 (Biotek), with an excitation wavelength of $488\text{ \ nm}$ and an emission wavelength of $525\text{ \ nm}$. In the imaging experiment, cells cultured in 24-well plates ($5 \times 10^{4}/\text{well}$) were treated with MeHg ($10\;\mu M$, $0.5\; h$) or $H_{2}O_{2}$ ($6\;\mu M$, $0.5\; h$). After washing with PBS, the nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) for 15 min at room temperature. Then the cells were incubated with $10\;\mu\text{mol}/L$ DCFH-DA in serum-free medium for $0.5\; h$ at 37°C. Finally, the resulting fluorescence was detected with a fluorescence microscope (Zeiss Axio Observer). Cells treated with $H_{2}O_{2}$ were used as the positive control. The intensity of fluorescence reflects the extent of oxidative stress.

Western Blotting Analysis {#s2.7}
-------------------------

To prepare the whole protein lysate, cells were washed three times with cold PBS, lysed in lysis buffer (RIPA lysis buffer containing 1% PMSF, obtained from Beyotime), incubated on ice for 15 min, and collected after $12,000\text{×}g$ centrifugation at 4°C for 15 min. The protein concentration was determined by a BCA protein assay reagent kit (Beyotime). A total of $60\;\mu g$ of cell total protein was separated using 10% or 12% SDS-PAGE, then transferred to a PVDF membrane (Millipore). After being blocked with 5% skim milk in TBST ($10\text{ \  \ mM}$ Tris--HCl, $120\text{ \  \ mM}$ NaCl, 0.1% Tween® 20, pH 7.4) for $2\; h$ at room temperature, the membranes were incubated with specific primary antibodies overnight at 4°C ([Table 1](#t1){ref-type="table"}). On the second day, the membranes were washed three times with TBST buffer and further incubated with HRP-labeled secondary antibodies at room temperature for $1\; h$, and then washed three times in TBST. Finally, signal density of the immunoblots was performed using the MiniChemi Mini Size Chemiluminescent Imaging System (Beijing Sage Creation Science Co., Ltd.) and analyzed with Image J software (National Institutes of Health).

###### 

Protein antibodies used for Western blotting.

Table 1 lists antibodies in the first column; the corresponding source, Catalog number, lot, and dilution are listed in the other columns.

  Antibodies                    Source                      Catalog no.   Lot        Dilution
  ----------------------------- --------------------------- ------------- ---------- ----------
  $\text{HIF-}1\alpha$          ImmunoWay                   YT2133        B3301      1:1,000
  $\text{HIF-}1\beta$           Cell Signaling Technology   D28F3         2          1:1,000
  GLUT-1                        ImmunoWay                   YT1928        B2801      1:1,000
  EPO                           ImmunoWay                   YM0237        B3701      1:1,000
  VEGF-A                        ImmunoWay                   YT5108        B0801      1:1,000
  $\beta\text{-actin}$          CMCTAG                      AT0048        380436SB   1:10,000
  Mouse antirabbit IgG-HRP      Santa Cruz Biotechnology    sc-2357       K0718      1:10,000
  $m\text{-IgG}\kappa$ BP-HRP   Santa Cruz Biotechnology    sc-516102     E2318      1:10,000

Adenovirus-Mediated $\text{HIF-}1\alpha$ Overexpression {#s2.8}
-------------------------------------------------------

Adenovirus carrying the $\text{HIF-}1\alpha$ gene was obtained from Hanbio Biotechnology Co., Ltd. Astrocytes were seeded in 6-well plates at a 60% confluence, and cells were transfected with pHBAd-EF1-MCS-GFP according to ${\text{multiplicity of infection }\left( \text{MOI} \right) = 30 \times 10}^{8}\text{PFU}/{mL}$ $8\; h$ later, cells were supplemented with fresh medium and continuously cultured for an additional $48\; h$ to observe transfection efficiency by means of Western blotting.

siRNA Transfection {#s2.9}
------------------

The small interfering RNAs (siRNAs) for $\text{HIF-}1\alpha$ were designed and purchased from Guangzhou Ribobio Co., Ltd. The sequences of the three siRNAs were as follows:

\#1 (siB07514101244) 5′-TCGACAAGCTTAAGAAAGA dTdT-3′,

\#2 (siB07514101312) 5′-GGACAATATAGAAGACATT dTdT-3′ and

\#3 (siG081230140326) 5′-CTGATAACGTGAACAAATA dTdT-3′.

Astrocytes were plated in 6-well plates at 60% confluence, transfected with $\text{HIF-}1\alpha$ siRNA ($50\text{ \ nM}$), or a negative control (NC, a scrambled sequence) siRNA ($50\text{ \ nM}$) with Lipofectamine®2000 in Opti-MEM medium (Invitrogen), according to the manufacturer's protocol. The transfected cells were incubated at 37°C for an additional $48\; h$ and validated the silencing efficacy via Western blotting analysis.

Total RNA Extraction and Quantitative Real-Time PCR (RT-PCR) {#s2.10}
------------------------------------------------------------

Total RNA was extracted from astrocytes using the TRIzol reagent (Invitrogen). Five hundred nanograms of total RNA were reverse-transcribed to cDNA using an RT reagent kit (TaKaRa), which was then amplified with SYBR green dye on a CFX96 Real-Time PCR Detection System (Bio-Rad). The relative quantification of mRNA levels was calculated using the standard $2^{‐\Delta\Delta\text{Ct}}$ relative quantification method.

The primers for rat $\text{HIF-}1\alpha$ and $\beta\text{-actin}$ were designed and synthesized by Shanghai Generay Biotech Co., Ltd (Shanghai, China), and the sequences were as follows:

$\text{HIF-}1\alpha$:

Forward primer: 5′-TCACAAATCAGCACCAAGCAC-3′

Reverse primer: 5′-AAGGGGAAAGAACAAAACACG-3′

$\beta\text{-actin}$:

Forward primer: 5′-CCTAGACTTCGAGCAAGAGA-3′

Reverse primer: 5′-GGAAGGAAGGCTGGAAGA-3′.

Animal Model {#s2.11}
------------

Male SD rats (8 wk old) weighing $200 \pm 20\; g$ were obtained from the Laboratory Animal Center of Jiangsu University (Accreditation Number: SCXK \[SU\] 2018-0012). The rats were housed in a temperature- and humidity-controlled room ($22 \pm 2{^\circ}C$ and $50 \pm 10\%$ relative humidity) with a $12\; h$:$12\; h$ light:dark cycle (dark phase from 1900 to 0700) and were maintained on standard laboratory chow with ad libitum access to water and food ($n = 6$ per cage). The rats were acclimatized for at least 7 d prior to MeHg exposure.

Rats were divided randomly into six groups ($n = 6$):

Group I: Normal saline was injected intraperitoneally for $0.5\; h$

Group II: MeHg \[$2\;{mg}/{kg}$ body weight (BW)\] was injected intraperitoneally for $0.5\; h$

Group III: MeHg ($4\;{mg}/{kg}$ BW) was injected intraperitoneally for $0.5\; h$

Group IV: MeHg ($6\;{mg}/{kg}$ BW) was injected intraperitoneally for $0.5\; h$

Group V: MeHg ($8\;{mg}/{kg}$ BW) was injected intraperitoneally for $0.5\; h$

Group VI: MeHg ($10\;{mg}/{kg}$ BW) was injected intraperitoneally for $0.5\; h$

At the end of the exposure period, the rats were anesthetized by intraperitoneal (IP) injection of pentobarbital to alleviate any potential discomfort and pain. Next, the brain cortices were rapidly frozen in liquid nitrogen and transferred to a $–{80}{^\circ}C$ freezer. All experimental procedures were conducted following a protocol approved by the Animal Care and Use Committee and Animal Ethics Committee of Jiangsu University (Accreditation Number: SYXK \[SU\] 2013-0036). All animals used in this study were treated humanely according to the institutional guidelines, with full consideration for the alleviation of distress and discomfort.

Statistical Analysis {#s2.12}
--------------------

All data are presented as the $\text{mean} \pm \text{standard\  \ deviation}$ (SD). All assays were repeated at least three times with at least three independently derived astrocyte cultures. Statistical significance was assessed by analysis of variance (ANOVA) with correction for multiple comparisons in post hoc analysis. CHX treatment assay was analyzed by a two-way ANOVA with Dunnett's post hoc test. Other multiple comparisons were analyzed by one-way ANOVA with Dunnett's or Tukey's post hoc test. All statistical analyses were performed using GraphPad Prism software. A *p* value of $< 0.05$ was considered to be statistically significant.

Results {#s3}
=======

Effects of Methylmercury on Astrocyte Proliferation, Cytotoxicity, and Production of ROS {#s3.1}
----------------------------------------------------------------------------------------

To investigate the effects of MeHg on cell proliferation and cytotoxicity in astrocytes, we incubated astrocytes with this organometal ($0–10\;\mu M$) for $0.5\; h$. The MTT assay and LDH leakage were subsequently assessed. As shown in [Figure 1A](#f1){ref-type="fig"}, compared with control cells, those treated with MeHg exhibited lower cell proliferation, which appeared to be concentration-dependent. MeHg treatment significantly increased LDH release in astrocytes, especially at concentrations of 5 and $10\mspace{9mu}\mu M$ ([Figure 1B)](#f1){ref-type="fig"}. Exposure to MeHg ($5$ and $10\mspace{9mu}\mu M$, $0.5\; h$) induced a ∼1.6-fold increase in astrocytic LDH release compared with controls ($p < 0.05$). Next, we analyzed the effects of MeHg on ROS production by 2′,7′-dichlorofluorescin diacetate (DCFH-DA) fluorescence. As is shown in [Figure 1C](#f1){ref-type="fig"}, MeHg at 5 and $10\mspace{9mu}\mu M$ caused a significant increase in ROS formation. Additionally, fluorescence images also showed that the fluorescence intensity of ROS was obviously enhanced in MeHg ($10\mspace{9mu}\mu M$, $0.5\; h$) group ([Figure 1D)](#f1){ref-type="fig"}.

![Cell proliferation, cytotoxicity and ROS production after treatment with MeHg for $0.5\; h$ in astrocytes. (A) Cell proliferation in astrocytes was measured using the MTT assay. (B) Cytotoxicity in astrocytes was detected via LDH release. (C) Effects of MeHg treatment on ROS production using the fluorescent probe DCFH-DA. The fluorescence intensity was detected by the microplate reader. (D) Representative images for ROS generation induced by MeHg ($10\;\mu M$, $0.5\; h$) treatment. $\text{Scale\  \ bar} = 100\;\mu m$. $H_{2}O_{2}$ ($6\;\mu M$, $0.5\; h$) was set as a positive control for ROS generation. Green fluorescence indicates ROS and blue (DAPI) indicates the nucleus. Note: Data are presented as $\text{mean} \pm \text{SD}$ from three independent experiments ($n = 3$). con, control (culture medium treatment without MeHg); DAPI, 4′,6-diamidino-2-phenylindole; DCFH-DA, 2′,7′-dichlorofluorescin diacetate; $H_{2}O_{2}$, hydrogen peroxide; LDH, lactate dehydrogenase; MeHg, methylmercury; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl diphenyltetrazolium bromide; ROS, reactive oxygen species. *\**$p < 0.05$ vs. control by one-way analysis of variance (ANOVA) with Dunnett's post hoc test.](ehp-127-127006-g001){#f1}

Effects of Methylmercury on the Expression of $\text{HIF-}1\alpha\text{-Related}$ Proteins in Astrocytes {#s3.2}
--------------------------------------------------------------------------------------------------------

We incubated astrocytes in the absence or presence of MeHg ($1–10\;\mu M$) for $0.5\; h$ and assessed $\text{HIF-}1\alpha$ and $\text{HIF-}1\beta$ expression by Western blotting. MeHg-treated astrocytes exhibited a significant reduction in $\text{HIF-}1\alpha$ expression in a concentration-dependent manner ([Figure 2A)](#f2){ref-type="fig"}. In contrast, $\text{HIF-}1\beta$ remained unaffected irrespective of the MeHg concentration ([Figure 2B)](#f2){ref-type="fig"}. Next, we analyzed the expression of $\text{HIF-}1\alpha$ targets (GLUT-1, EPO, and VEGF-A) in astrocytes treated with various concentrations of MeHg. A significant decrease in the expression of GLUT-1, EPO, and VEGF-A proteins was observed in astrocytes treated with $10\mspace{9mu}\mu M$ MeHg for $0.5\; h$ ($p < 0.05$) ([Figure 2C)](#f2){ref-type="fig"}. These results are consistent with the ability of MeHg to decrease astrocytic $\text{HIF-}1\alpha$ levels, followed by a decrease in, GLUT-1, EPO, and VEGF-A expression.

![Effects of MeHg on the expression of $\text{HIF-}1\alpha –\text{related}$ proteins in astrocytes. (A) Western blotting for $\text{HIF-}1\alpha$ in astrocytes following MeHg (0, 1, 2.5, 5 or $10\;\mu M$, $0.5\; h$) exposure. (B) Western blotting for $\text{HIF-}1\beta$ in astrocytes following MeHg (0, 1, 2.5, 5, or $10\;\mu M$, $0.5\; h$) exposure. (C) Effect of MeHg (0, 1, 2.5, 5, or $10\;\mu M$, $0.5\; h$) exposure on the expression of the downstream proteins of $\text{HIF-}1\alpha$, including GLUT-1, EPO, and VEGF-A. $\beta\text{-actin}$ was used as the internal control. Note: Data are presented as $\text{mean} \pm \text{SD}$ from three independent experiments ($n = 3$). con, control (culture medium treatment without MeHg); EPO, erythropoietin; GLUT-1, glucose transporter 1; $\text{HIF-}1\alpha$, Hypoxia-inducible $\text{factor-}1\alpha$; $\text{HIF-}1\beta$, Hypoxia-inducible $\text{factor-}1\beta$; MeHg, methylmercury; VEGF-A, vascular endothelial growth factor A. \*$p < 0.05$ vs. control by one-way ANOVA with Dunnett's post hoc test.](ehp-127-127006-g002){#f2}

Effects of Protein Synthesis, Proteasome, and PHD Inhibitors on Protein Expression of $\text{HIF-}1\alpha$ and Downstream Effectors in Methylmercury-Treated Astrocytes {#s3.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine the means by which MeHg regulated $\text{HIF-}1\alpha$ expression, we analyzed the expression of the $\text{HIF-}1\alpha$ gene with RT-PCR. As shown in [Figure 3A](#f3){ref-type="fig"}, MeHg pretreatment did not affect $\text{HIF-}1\alpha$ mRNA levels. Therefore, we further explored the potential causes of the significant reduction in $\text{HIF-}1\alpha$ levels caused by MeHg in astrocytes. CHX is a broad-spectrum and nonspecific protein synthesis inhibitor, and astrocytes were harvested after CHX pretreatment ($400\;\mu M$) for 0.5, 1, and $2\; h$ with and without MeHg treatment ($10\mspace{9mu}\mu M$, $0.5\; h$). In addition, MeHg treatment alone group ($10\mspace{9mu}\mu M$ for 0.5, 1, and $2\; h$) was also established. Then, $\text{HIF-}1\alpha$ protein expression was analyzed ([Figure 3B)](#f3){ref-type="fig"}. In comparison with the control group, the protein level of $\text{HIF-}1\alpha$ in CHX alone group decreased in a time-dependent manner. Notably, when compared with the corresponding time point of CHX treatment alone group, the level of $\text{HIF-}1\alpha$ protein was found to be significantly lower in the $\text{CHX} + \text{MeHg}$ group ($p < 0.05$, [Figure 3B)](#f3){ref-type="fig"}. We pretreated astrocytes with or without MG132 ($1\;\mu M$, $24\; h$), a proteasome inhibitor, followed by $10\;\mu M$ MeHg, and incubated the cells for an additional $0.5\; h$. The cells were harvested at the end of the treatment, and the levels of $\text{HIF-}1\alpha$ and its targets were measured via Western blotting. As shown in [Figure 3C](#f3){ref-type="fig"}, MG132 treatment inhibited the significant MeHg-induced reduction in $\text{HIF-}1\alpha$ and its target proteins in astrocytes. Previous research has suggested that $\text{HIF-}1\alpha$ degradation is attributable to the activation of proline hydroxylase (PHD) ([@c69]). To define the potential contribution of PHD-mediated inhibition of $\text{HIF-}1\alpha$ in response to MeHg treatment, we treated astrocytes with $1\text{ \ mM}$ DHB \[a small-molecule prolyl hydroxylase (PHD) inhibitor\] ([@c89]) for $6\; h$ and exposed astrocytes to $10\;\mu M$ MeHg for $0.5\; h$. Notably, compared with cells treated with MeHg alone, astrocytic $\text{HIF-}1\alpha$ expression in cells treated with MeHg and either the proteasome inhibitor ([Figure 3C](#f3){ref-type="fig"}) or the PHD inhibitor ([Figure 3E](#f3){ref-type="fig"}) was significantly higher. In addition, both the proteasome inhibitor and PHD inhibitor restored MeHg-inhibited cell proliferation ([Figure 3D and 3F)](#f3){ref-type="fig"}.

![Effects of protein expression of $\text{HIF-}1\alpha$ and its downstream effectors and effects on cell proliferation induced by CHX, MG132, or DHB in MeHg-treated astrocytes. (A) Astrocytes were treated with MeHg (0, 1, 2.5, 5, or $10\;\mu M$, $0.5\; h$) and $\text{HIF-}1\alpha$ mRNA was evaluated. mRNA was normalized to $\beta\text{-actin}$ and plotted relative to the control. \*$p < 0.05$ vs. the control by one-way ANOVA with Dunnett's post hoc test. (B) Cells were pretreated with $400\;\mu M$ CHX for 0.5, 1 and $2\; h$ and then exposed to $10\;\mu M$ MeHg for $0.5\; h$. MeHg treatment alone group ($10\;\mu M$ for 0.5, 1 and $2\; h$) was also established. $\text{HIF-}1\alpha$ protein levels were analyzed by western blotting. $\beta\text{-actin}$ was used to normalize the protein level and the intensities were presented as fold changes relative to the control. \*$p < 0.05$ vs. the control by one-way ANOVA with Dunnett's post hoc test. ^\#^$p < 0.05$ the $\text{CHX} + \text{MeHg}$ group vs. the corresponding time point of CHX alone group by two-way ANOVA with Dunnett's post hoc test. (C) Cells were pretreated with MG132 ($1\;\mu M$, $24\; h$) and then treated with $10\;\mu M$ MeHg for $0.5\; h$. Western blotting was used to evaluate protein levels of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A. (D) Effect of MG132 ($1\;\mu M$, $24\; h$) on the cell proliferation was evaluated using an MTT assay. (E) Effect of DHB pretreatment ($1\text{ \ mM}$, $6\; h$) on the expression of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A was detected by western blotting. (F) Effect of DHB pretreatment ($1\text{ \ mM}$, $6\; h$) on the cell proliferation was determined by an MTT assay. For Western blotting analyses, $\beta\text{-actin}$ was used to normalize the protein level. Note: Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test. Data are presented as $\text{mean} \pm \text{SD}$ from three independent experiments ($n = 3$). CHX, cycloheximide; con, control (culture medium treatment without MeHg); DHB, 3,4-Dihydroxybenzoic acid; EPO, erythropoietin; GLUT-1, glucose transporter 1; $\text{HIF-}1\alpha$, Hypoxia-inducible $\text{factor-}1\alpha$; MeHg, methylmercury; MG132, proteasome inhibitor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl diphenyltetrazolium bromide; VEGF-A, vascular endothelial growth factor A. \*$p < 0.05$ vs. control, ^\#^$p < 0.05$ vs. MeHg only-group.](ehp-127-127006-g003){#f3}

Effects of Pharmacologic and Genetic Manipulation of $\text{HIF-}1\alpha$ on Cell Proliferation {#s3.4}
-----------------------------------------------------------------------------------------------

We hypothesized that decreased $\text{HIF-}1\alpha$ protein contributes to astrocytic cytotoxicity. To further confirm this hypothesis, we treated astrocytes with $\text{CoCl}_{2}$ ($200\;\mu M$, $0.5\; h$) or 2-MeOE2 ($10\;\mu M$, $0.5\; h$) in the absence or presence of MeHg ($0.5\; h$ exposure). We used $\text{CoCl}_{2}$, an inducer of $\text{HIF-}1\alpha$ expression ([@c94]), and 2-MeOE2, a $\text{HIF-}1\alpha$ inhibitor ([@c25]; [@c74]; [@c77]), to regulate $\text{HIF-}1\alpha$ expression in MeHg-treated astrocytes ([Figure 4A and 4C)](#f4){ref-type="fig"}. Analogous to the data shown in [Figure 3D and 3F](#f3){ref-type="fig"}, overexpression of $\text{HIF-}1\alpha$ protein mitigated the MeHg-reduced cell proliferation in astrocytes ($p < 0.05$) ([Figure 4B](#f4){ref-type="fig"}), whereas down-regulation of $\text{HIF-}1\alpha$ protein significantly aggravated the decline in astrocytic proliferation caused by MeHg ($p < 0.05$) ([Figure 4D)](#f4){ref-type="fig"}. To confirm this observation, we further used siRNA and adenovirus overexpression, which target the $\text{HIF-}1\alpha$ gene ([Figure 4E to 4H](#f4){ref-type="fig"}). Consistent with the results of $\text{CoCl}_{2}$ and 2-MeOE2 treatment, overexpression of $\text{HIF-}1\alpha$ significantly attenuated the decline in MeHg-induced cell proliferation ([Figure 4F](#f4){ref-type="fig"}), whereas inhibition of $\text{HIF-}1\alpha$ significantly increased the decline in cell proliferation ([Figure 4H](#f4){ref-type="fig"}; $p < 0.05$).

![Effects of pharmacologic and genetic manipulation of $\text{HIF-}1\alpha$ on cell proliferation. (A) Astrocytes were pretreated with $\text{CoCl}_{2}$ ($200\;\mu M$, $0.5\; h$) and then treated with $10\;\mu M$ MeHg for $0.5\; h$. Western blotting was used to evaluate protein levels of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A. (B) Effect of $\text{CoCl}_{2}$ pretreatment ($200\;\mu M$, $0.5\; h$) on the cell proliferation was evaluated using an MTT assay. (C) Effect of 2-MeOE2 pretreatment ($10\;\mu M$, $0.5\; h$) on the expression of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A was detected by Western blotting. (D) Effect of 2-MeOE2 pretreatment ($10\;\mu M$, $0.5\; h$) on the cell proliferation was evaluated using an MTT assay. For Western blotting analyses, representative blots are shown, and the intensities are presented as fold changes relative to the control group ($\beta\text{-actin}$ as the internal control). \*$p < 0.05$ vs. control, ^\#^$p < 0.05$ vs. MeHg-only group. (E) The protein expression levels of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A after overexpression of $\text{HIF-}1\alpha$. \*$p < 0.05$ vs. HBAD-null group. (F) Effect of adenovirus-induced $\text{HIF-}1\alpha$ overexpression on the decrease in MeHg-induced cell proliferation as determined by an MTT assay. \*$p < 0.05$ vs. control group, ^\#^$p < 0.05$ vs. $\text{MeHg} + \text{HBAD-null}$ group. (G) Effect of $\text{HIF-}1\alpha$ siRNA on the protein expression of $\text{HIF-}1\alpha$, GLUT-1, EPO, and VEGF-A. (H) Effect of $\text{HIF-}1\alpha$ siRNA on the MeHg-induced decrease in cell proliferation. Note: Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test. Data are presented as the $\text{mean} \pm \text{SD}$ from three independent experiments ($n = 3$). $\text{CoCl}_{2}$, cobalt chloride; con, control (culture medium treatment without MeHg); EPO, erythropoietin; GLUT-1, glucose transporter 1; HBAD, pHBAd-EF1-MCS-GFP; $\text{HIF-}1\alpha$, Hypoxia-inducible $\text{factor-}1\alpha$; 2-MeOE2, 2-methoxyestradiol; MeHg, methylmercury; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl diphenyltetrazolium bromide; nc siRNA, negative control (scrambled sequence) siRNA; siRNA, small interfering RNA; VEGF-A, vascular endothelial growth factor A. \*$p < 0.05$ vs. nc siRNA group. \*$p < 0.05$ vs. control group, ^\#^$p < 0.05$ vs. $\text{MeHg} + \text{nc\  \ siRNA}$ group.](ehp-127-127006-g004){#f4}

$\text{HIF-}1\alpha$ Protein Expression and Cell Proliferation after Pretreatment with Antioxidants in Methylmercury-Treated Astrocytes {#s3.5}
---------------------------------------------------------------------------------------------------------------------------------------

We investigated whether ROS production were associated with decreased $\text{HIF-}1\alpha$ expression in MeHg-exposed astrocytes. Astrocytes were pretreated with NAC ($2.5\text{ \ mM}$, $4\; h$) and Trolox ($2.5\text{ \ mM}$, $4\; h$) followed by $10\;\mu M$ MeHg for $0.5\; h$. NAC and Trolox are antioxidants that are commonly used to mitigate ROS ([@c3]; [@c10]; [@c56]). As shown in [Figures 5A and 5C](#f5){ref-type="fig"}, cells pretreated with either NAC or Trolox and then treated with MeHg exhibited higher $\text{HIF-}1\alpha$ protein levels, similar to those of control cells, than those treated with MeHg alone. Pretreated cells exhibited higher levels (as much as $\sim 30\%$) of cell proliferation than those treated with MeHg alone ($p < 0.05$) ([Figure 5B and 5D)](#f5){ref-type="fig"}.

![$\text{HIF-}1\alpha$ protein expression and cell proliferation after pre-treatment with antioxidants in MeHg-treated astrocytes. (A) Effect of NAC pretreatment ($2.5\text{ \ mM}$, $4\; h$) on $\text{HIF-}1\alpha$ protein expression. (B) Effect of NAC pretreatment on the decreased cell proliferation induced by MeHg. (C) Effect of Trolox pretreatment ($2.5\text{ \ mM}$, $4\; h$) on $\text{HIF-}1\alpha$ protein expression. (D) Effect of Trolox pretreatment on the MeHg-induced decrease in cell proliferation. Note: Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test. Data are presented as the $\text{mean} \pm \text{SD}$ from three independent experiments ($n = 3$). con, control (culture medium treatment without MeHg); $\text{HIF-}1\alpha$, Hypoxia-inducible $\text{factor-}1\alpha$; MeHg, methylmercury; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl diphenyltetrazolium bromide; NAC, *N*-acetyl-cysteine, Trolox, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid. \*$p < 0.05$ vs. control, ^\#^$p < 0.05$ vs. MeHg-only group.](ehp-127-127006-g005){#f5}

Protein Expression of $\text{HIF-}1\alpha$ and Downstream Effectors following MeHg Administration in *in Vivo* Rat Models {#s3.6}
-------------------------------------------------------------------------------------------------------------------------

Finally, to evaluate the *in vivo* effects of MeHg on $\text{HIF-}1\alpha$ protein expression, we established a SD rat model. Animals were administered with MeHg (0, 2, 4, 6, 8, and $10\;{mg}/{kg}$, each group with 6 rats) by intraperitoneal injection and sacrificed $0.5\; h$ later. The expression of $\text{HIF-}1\alpha$ and its target proteins in brain tissues was measured by Western blotting. As shown in [Figure 6](#f6){ref-type="fig"}, MeHg treatment significantly decreased the expression of $\text{HIF-}1\alpha$ and its targets, especially in rats exposed to $8\;{mg}/{kg}$ and $10\;{mg}/{kg}$ MeHg ($p < 0.05$).

![Protein expression of $\text{HIF-}1\alpha$ and downstream effectors following MeHg administration in *in vivo* rat models. Adult Sprague-Dawley rats were administered with MeHg (0, 2, 4, 6, 8, $10\;{mg}/{kg}$) by intraperitoneal injection for $0.5\; h$. Whole brain lysates were analyzed by Western blotting for the indicated proteins. Note: Data are presented as $\text{mean} \pm \text{SD}$ ($n = 6\text{ \ rats}/\text{group}$). con, control (intraperitoneal injection of saline); EPO, erythropoietin; GLUT-1, glucose transporter 1; $\text{HIF-}1\alpha$, Hypoxia-inducible $\text{factor-}1\alpha$; MeHg, methylmercury; VEGF-A, vascular endothelial growth factor A. \*$p < 0.05$ vs. control group by one-way ANOVA with Dunnett's post hoc test.](ehp-127-127006-g006){#f6}

Discussion {#s4}
==========

In the present study, we report that, compared with the vehicle control, treatment with 5 or $10\,\mu M$ MeHg for $0.5\; h$ resulted in lower cell proliferation and higher ROS generation in primary rat astrocytes, and these results were associated with lower expression of $\text{HIF-}1\alpha$. To define the mechanism(s) of the MeHg-induced alteration in $\text{HIF-}1\alpha$ expression, first we detected the mRNA level of $\text{HIF-}1\alpha$ after MeHg treatment. The results showed that MeHg exposure resulted in a significant reduction in $\text{HIF-}1\alpha$ levels without affecting $\text{HIF-}1\alpha$ transcription. Then, we speculated that whether MeHg affected the degradation of $\text{HIF-}1\alpha$ protein. The results showed that treating cells with $\text{CHX} + \text{MeHg}$ results in lower protein expression of $\text{HIF-}1\alpha$ than does treating cells with CHX alone in three different time points. Because CHX blocks protein synthesis, it would stand to reason that the effect of MeHg in these cells is associated with protein degradation. Additionally, we also demonstrated that the proteasome inhibitor (MG132) and the PHD inhibitor (DHB), both of which block protein degradation of $\text{HIF-}1\alpha$, partially restored the inhibitory effect of MeHg on $\text{HIF-}1\alpha$ protein, further suggesting that the MeHg-induced decrease in $\text{HIF-}1\alpha$ protein is due to the promoted degradation. Furthermore, taking advantage of genetic and pharmacological methods to alter inherent levels of the $\text{HIF-}1\alpha$ protein, we provide evidence directly linking MeHg toxicity with $\text{HIF-}1\alpha$ inhibition. It is noteworthy that lower $\text{HIF-}1\alpha$ protein expression was related to the production of ROS, as demonstrated by NAC and Trolox. Taken together, our novel observations suggest that ROS act as an important regulator of $\text{HIF-}1\alpha$ inhibition in MeHg-treated astrocytes and that overexpression of $\text{HIF-}1\alpha$ may afford a novel neuroprotective effect in the treatment of MeHg-induced neurotoxicity. Moreover, we also found that MeHg inhibited the expression of $\text{HIF-}1\alpha$ in the SD rat brain, which better revealed the relationship between MeHg and the $\text{HIF-}1\alpha$ signaling pathway found in the *in vitro* and *in vivo* experiments.

MeHg is an established neurotoxicant ([@c6]; [@c29]; [@c31]; [@c39], [@c40]), whose mechanism(s) of toxicity have yet to be fully understood; however, oxidative stress seems to play a role ([@c7]; [@c81]; [@c49]). Oxidative stress is one of the known mechanisms for the induction of $\text{HIF-}1\alpha$. Previous studies have consistently shown that metals, such as lead ([@c33]), aluminum ([@c67]), manganese ([@c45]), and zinc ([@c72]; [@c75]), as well as other xenobiotics, such as isoflurane ([@c21]; [@c93]), can increase $\text{HIF-}1\alpha$ expression. In contrast, concentration-dependent inhibition of $\text{HIF-}1\alpha$ in Hep3B cells has been reported in response to cadmium and inorganic mercury (Hg) treatment ([@c48]).

We speculated that two factors contribute to the decreased level of $\text{HIF-}1\alpha$ protein in response to MeHg treatment. First, MeHg-induced mitochondrial damage might cause a reduction in oxygen consumption and increase relative oxygen content, leading to redistribution of oxygen and binding to PHD and an increase in PHD activity ([@c96]), whereas other metals, including inorganic mercury, mimicked a hypoxic state and induced pseudohypoxia to promote the translocation of $\text{HIF-}1\alpha$ ([@c67]). MeHg did not change the level of $\text{HIF-}1\alpha$ in brain microvascular pericytes ([@c47]). Second, MeHg might increase 2-oxoglutarate (2-OG) levels, a cofactor of PHD. 2-OG has been shown to increase PHD activity, resulting in increased degradation of $\text{HIF-}1\alpha$ and a net decrease in $\text{HIF-}1\alpha$ protein ([@c34]; [@c68]; [@c70]). As shown in [Figure 3](#f3){ref-type="fig"}, MeHg appeared to have activated PHD and UPS, thus promoting $\text{HIF-}1\alpha$ degradation.

$\text{HIF-}1\alpha$ regulates the expression of a large number of genes that are involved in glucose metabolism, energy production, angiogenesis, migration, and other cellular processes ([@c64]; [@c83]). Thus, reduced availability of $\text{HIF-}1\alpha$ and the subsequent reduction in expression of its target genes may cause cellular dysfunction. VEGF-A, GLUT-1, and EPO are typical downstream target proteins of $\text{HIF-}1\alpha$ ([@c9]; [@c30]; [@c71]; [@c83]). VEGF-induced angiogenesis has previously been shown to improve the blood supply to neurons and slow the clinical deterioration in Alzheimer's disease ([@c17]). VEGF and EPO have been shown to improve tissue oxygen content by promoting erythropoiesis and angiogenesis, which may stimulate genes involved in glucose transport and metabolism ([@c9]; [@c83]). It is noteworthy that $\text{HIF-}1\alpha$ complexes can regulate the biological functions of various genes, such as those involved in vascular growth, oxygen transport, and energy metabolism ([@c32]). Thus, we suggest that the mechanism of MeHg neurotoxicity involves, at least in part, a reduction in $\text{HIF-}1\alpha$ and its downstream proteins (GLUT-1, EPO, and VEGF-A), leading to secondary alterations in blood flow, tissue oxygenation, and ATP production. In addition, studies on the regulation of PHD have generated interest as investigational drugs for anemia and neurodegenerative diseases. The use of a small molecule of $\text{HIF-}1\alpha$ PHD inhibitor (FG-4592), has been promoted to clinical trials for treating anemia by increasing erythropoiesis through $\text{HIF-}1\alpha$ mediated transcription ([@c16]; [@c26]; [@c43]), as well as for treating Parkinson's disease by $\text{HIF-}1\alpha\text{-targeted}$ positive regulation of redox biology and mitochondrial function ([@c62]). In the present study, the suppression of MeHg toxicity by both $\text{CoCl}_{2}$ and adenovirus-targeted $\text{HIF-}1\alpha$ overexpression suggested that activation of the $\text{HIF-}1\alpha$ pathway can reverse inhibition of cell proliferation by MeHg ([Figure 4](#f4){ref-type="fig"}). Thus, we suggest that $\text{HIF-}1\alpha$ can be pursued as a novel target for MeHg poisoning.

MeHg-induced toxicity is mediated, at least in part, by oxidative stress ([@c76]; [@c98]). In addition, rapid degradation of $\text{HIF-}1\alpha$ may result from ROS generation ([@c13]; [@c19]; [@c46]; [@c52]; [@c61]; [@c82]). We initially considered that ROS generation could play a role in the altered $\text{HIF-}1\alpha$ protein expression to mediate MeHg toxicity. Treatment of rat astrocytes with oxygen radical scavengers (NAC and Trolox) resulted in higher $\text{HIF-}1\alpha$ protein expression and increased cell proliferation ([Figure 5](#f5){ref-type="fig"}), suggesting that detoxification of ROS by $\text{HIF-}1\alpha$ is associated with its neuroprotective effects. Reductions in $\text{HIF-}1\alpha$ expression in MeHg-treated astrocytes and rats suggest that the up-regulation of $\text{HIF-}1\alpha$ affords neuroprotective effects. Taking into account the limitations of the pharmacological and genetic regulations of clinical toxicity and the ability of antioxidants to promote $\text{HIF-}1\alpha$ expression, the use of antioxidants should be considered for clinical detoxification. However, MeHg can affect many cellular and molecular functions if the MeHg exposure concentrations and duration are sufficient. Thus, additional research on the toxicological significance of $\text{HIF-}1\alpha$ suppression by acute exposure to MeHg is warranted, in addition to a more precise delineation of its protective mechanisms.

In conclusion, we demonstrated that MeHg led to astrocytic neurotoxicity *in vitro* by reducing levels of $\text{HIF-}1\alpha$ and its downstream proteins, which may result from increasing PHD activity, which in turn promoted $\text{HIF-}1\alpha$ degradation. Furthermore, the up-regulation of $\text{HIF-}1\alpha$ imparted protection against MeHg neurotoxicity. Taken together, these findings---from both *in vivo* and *in vitro* experiments---suggest that $\text{HIF-}1\alpha$ may be as of yet an unrecognized and important mediator or regulator of MeHg-induced neurotoxicity, and this means of increasing $\text{HIF-}1\alpha$ activation in astrocytes may afford a therapeutic strategy for mitigating MeHg poisoning.
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